Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

A cancer expert has shared the five types of cancer which are considered the most "lethal", and claimed people diagnosed with ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds ...

"To our knowledge, our study represents the first randomized, global study to report data for an anti-TIGIT monoclonal antibody in hepatocellular carcinoma," Finn and colleagues wrote in Lancet ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...